Startup · Sarasota–Bradenton
Omeza
Regenerative wound-care company whose FDA-cleared Omeza Collagen Matrix, derived from marine lipids and cold-water fish peptides, supports healing of chronic wounds such as diabetic foot ulcers.
HealthTechBiotech & Life SciencesEarly-stage
Medtech / regenerative wound-care startup with an FDA-cleared drug-device wound matrix.
Notable: Closed an $8.5M Series A in spring 2026 co-led by Astanor and BluKap Ventures (with Catalyst Investments and the Florida Opportunity Fund); lead product OCM is FDA-cleared with case studies showing 90-100% wound closure at 12 weeks.